Background: European Cubicin ® Outcomes Registry and Experience (EU-CORE) was a retrospective, non-interventional, multicenter registry that collected real-world clinical outcomes following daptomycin use for the treatment of Gram-positive infections. EU-CORE data from patients with infective endocarditis (IE) who underwent heart valve replacement were analysed. Methods: Clinical outcomes were assessed as success (cured or improved), failure, or nonevaluable. Adverse events (AEs) were recorded for up to 30 days after daptomycin treatment.
Introduction
Valvular disease associated with infective endocarditis (IE) often requires both surgery and antibiotic therapy. 1, 2 Despite advances in medical care, heart valve dysfunction remains one of the major causes of morbidity and mortality in patients with IE. 1 Other sequelae include neurologic, renal, musculoskeletal, and systemic infection complications. Studies suggest that heart valve surgery is potentially life saving 3 and is often indicated in patients with life-threatening cardiac conditions with or without proven IE. 4 Staphylococci, streptococci, and enterococci are among the most common causative pathogens of IE. Staphylococcus aureus [both methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)] is a predominant pathogen of right-sided IE (RIE). 2 S. aureus (mainly MRSA) and Streptococcus species are the most common causative pathogens of leftsided IE (LIE). 5 Coagulase-negative staphylococci (CoNS) are reported to be mostly associated with prosthetic valve endocarditis (PVE). 6 S. aureus and CoNS are often found in patients with health careassociated IE, acquired during hospitalization or following invasive procedures such as surgeries. 7 Enterococcal IE is less frequent and is generally difficult-to-treat due to higher rates of resistance to older antibiotics. 6, 8 IE caused by S. aureus is associated with complications more frequently than that caused by other pathogens (stroke, 21.3% versus 14.3%; systemic emboli, 27.1% versus 18.7%; persistent bacteraemia, 17.0% versus 5.2%; and inhospital mortality, 22.4% versus 14.6%). 9 All patients with IE require antibiotic therapy. Although >50% of cases can be managed with antibiotic therapy alone, 2 heart valve replacement in combination with antibiotic treatment is recommended in high-risk patients. 10 Guidelines recommend vancomycin treatment for native valve IE caused by MRSA, with daptomycin as an alternative treatment. [11] [12] [13] [14] Daptomycin is superior to vancomycin for the treatment of MSSA and MRSA bacteraemia with vancomycin minimum inhibitory concentration (MIC) > 1 mg/l. 14 In the case of PVE caused by MRSA, vancomycin in combination with rifampin and gentamicin is recommended. 13, 14 Daptomycin is a therapeutic option for Grampositive infections in patients with IE. 8, 15, 16 It is approved for the treatment of RIE caused by S. aureus at a dose of 6 mg/kg/day and has been reported to exhibit similar efficacy against both MSSA and MRSA. 17, 18 High-dose (>6 and up to 12 mg/kg/day) daptomycin is recommended in difficult-to-treat infections by national and international guidelines owing to its concentrationdependent pharmacokinetics. [12] [13] [14] 19 Reports from real-world experience have shown that daptomycin is equally effective in the treatment of LIE and RIE. [20] [21] [22] [23] Although these reports highlighted the effectiveness and safety of daptomycin in patients with IE, data on treatment outcomes in such patients with heart valve replacement are scarce.
The present analysis from European Cubicin ® Outcomes Registry and Experience (EU-CORE) retrospectively assessed the real-world clinical experience with daptomycin use for the treatment of Gram-positive infections in a subgroup of patients with IE who underwent heart valve replacement.
Methods
The present subgroup analysis of EU-CORE, a non-interventional, multicenter, retrospective, patient registry, 24 included data from patients with IE who underwent heart valve replacement. The protocol was approved by the health authority and an institutional review board (IRB) or ethics committee (EC) in each country and a written informed consent was obtained from patients according to the requirements of the IRB or EC and/or the local data privacy regulations. Data from the registry were collected using standardized case report forms for patients who had received at least one dose of daptomycin between January 2006 and April 2012. Supplementary and 2-year follow-up (until 2014) data were collected for patients with IE.
The clinical outcomes were assessed by the investigators at the end of therapy as cured, improved, failed, or non-evaluable according to protocoldefined criteria. Clinical success was defined as outcomes of cured or improved. Time to improvement was also recorded. Furthermore, the reasons for discontinuing daptomycin therapy and other antibiotics prescribed following daptomycin were also recorded.
Assessments IE was diagnosed according to the modified Duke criteria. 25 The duration of treatment was assessed based on the number of inpatient and outpatient days the patient received daptomycin therapy, even if the treatment was non-consecutive. Use of daptomycin alone or in combination with other antibiotics was recorded.
Long-term follow-up assessments were performed for up to 24 months after completion of daptomycin therapy.
All patients who received at least one dose of daptomycin were included in the safety analysis. Adverse events (AEs) and serious AEs (SAEs) were recorded during daptomycin treatment and for up to 30 days after treatment. AEs were recorded regardless of their relationship to daptomycin, and the severity was determined by the local investigators.
Statistical analyses were performed using Statistical Analysis System (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA). Inferential analyses were not conducted because of the nature of the study and no formal statistical methodology other than simple descriptive statistics was used. All analyses were considered to be explanatory. Numerical variables were summarized as arithmetic mean, standard deviation, median, minimum, first quartile, third quartile, and maximum for continuous variables and as absolute and relative frequencies for categorical variables. 23 
Results

Prescribing patterns
Overall, 108 (54.5%) patients received daptomycin at a dose of 6 mg/kg/day and 13 (6.6%) received 4 mg/kg/day, whereas 50 (25.3%) received doses >6 mg/kg/day [>8 mg/kg, 33 (16.7%)]. The median total duration of daptomycin treatment was 21 days (range, 1-112). Most of the patients (n = 166; 83.8%) received daptomycin as second-line treatment and a common reason of switching over to daptomycin treatment was failure of the prior antibiotics (n = 80; 40.4%), including glycopeptides such as vancomycin. The median duration of prior antibiotic therapy used to treat IE ranged from 6 to 10 days. Daptomycin was administered as first-line treatment in 29 (14.6%) patients. Concomitant antibiotics with daptomycin were prescribed in 76.8% of inpatients. Rifampicin was received concomitantly in 62 (31.3%) patients. In addition, other most commonly prescribed concomitant antibiotics were aminoglycosides (29.3%) and carbapenems (18.2%). Concomitant antibiotics such as carbapenems were most likely used for the treatment of other significant underlying infections.
Efficacy
The overall clinical success rate with daptomycin treatment was 83.3% (LIE, 83.1%; RIE, 81.0%; LRIE, 90.9%): 86.2% with first-line and 82.5% with second-line treatment. Daptomycin resulted in high clinical success rates in patients with S. aureus (88.4%; MRSA, 80.0%) and CoNS (81.1%) infections (Figure 1) .
The clinical success rate was numerically higher with high-dose (>6 mg/kg/day) daptomycin treatment ( Figure 2 ). The overall clinical success rate in patients followed for up to 2 years was 90.7% (39/43).
Safety
Overall AEs and SAEs regardless of daptomycin treatment were reported in 47 (23.7%) and 36 (18.2%) patients, respectively. AEs possibly related to daptomycin treatment were reported in 6 (3.0%) patients; of those 4 (2.0%) were SAEs. The most commonly reported AEs possibly related to daptomycin treatment were increased blood creatine phosphokinase (CPK; 1.5%), followed by 0.5% each of eosinophilic pneumonia, rash, cholestasis, rhabdomyolysis, and agranulocytosis. Blood CPK elevation as a SAE possibly related to daptomycin was reported in 1 (0.5%) patient. 
Discussion
There have been significant advances with respect to antimicrobial treatment of IE, however eradication of infection often requires surgical intervention in addition to antibiotic therapy. 26 This subgroup analysis from the EU-CORE study illustrated the real-world use of daptomycin in patients with IE who underwent heart valve replacement, expanding on the results from previous reports in patients with IE. 20, 23 In this analysis, S. aureus (MSSA and MRSA) and CoNS were the most commonly identified primary pathogens. The results showed that the clinical effectiveness of daptomycin in patients with IE who underwent heart valve replacement was high against infections caused by various Grampositive bacteria. Moreover, daptomycin showed a favourable safety profile in this patient population. These findings are consistent with those from published reports showing the effectiveness and tolerability of daptomycin treatment in patients with IE. 15, 17, 23 Moreover, Kornberger et al. 16 recently reported high clinical success rates (87.0%) with daptomycin in patients with Grampositive infections after cardiac surgery.
Data from this real-world analysis indicated that daptomycin was successfully used for the treatment of patients with RIE (approved indication) as well as the treatment of those with LIE and LRIE undergoing heart valve replacement. Daptomycin showed high clinical success rates against infections caused by S. aureus and CoNS, including resistant pathogens, in patients with IE undergoing heart valve replacement. Furthermore, daptomycin was shown to be effective against enterococcal infections in this patient cohort. These results are in line with published reports suggesting bactericidal activity of daptomycin against resistant Gram-positive pathogens causing IE. 23, 27 While the total duration of daptomycin therapy was comparatively short (approximately 21 days), many patients received prior antibiotics and some were switched after daptomycin therapy to other (e.g. step-down) antibiotics. High-dose daptomycin has been shown to be associated with higher success rates. This finding is consistent with that from an earlier report in patients with IE. 27 Several treatment guidelines also recommend the use of daptomycin at higher doses (>6 mg/kg/day) in the treatment of patients with IE. 11, 12, 14 High-dose daptomycin in combination with ceftaroline for 6 weeks successfully treated patients with aortic PVE caused by MRSA. 28 Daptomycin was mostly used as a second-line treatment; however, the clinical success rate was higher when daptomycin was used as a first-line treatment. Seaton et al. 29 reported higher clinical success rates with first-line as compared with second-line daptomycin treatment in patients with MRSA infections. These results are further supported by Cervera et al., 18 suggesting the use of high-dose daptomycin as first-line treatment in patients with IE. The international treatment guidelines support the use of higher doses of daptomycin in the treatment of patients with IE. 11, 19 Treatment with suboptimal doses below the approved one (6 mg/kg/day) to treat IE is associated with a lower clinical success rate and should be avoided in this patient population.
In the present analysis, the long-term, follow-up results for up to 2 years indicated high sustained clinical success rates with daptomycin in patients with IE undergoing heart valve replacement and suggested daptomycin as an effective treatment option in this patient population with IE.
AEs, such as blood CPK elevation, neuropathy, and eosinophilic pneumonia, which have been reported with daptomycin use, were uncommon in this subgroup. The safety results are consistent with those previously reported, demonstrating the safety and tolerability of daptomycin in patients with IE. 22, 23 Furthermore, no new or unexpected safety findings were observed in this patient cohort with IE undergoing heart valve replacement.
This study has a few limitations, such as the relatively small number of patients in the subgroup analysis. The study was not aimed to examine the individual benefits of surgical intervention versus antibiotic therapy or the relative benefits of antibiotic combination therapy. In addition, this was a real-world, observational study, with a non-randomized and non-comparative design.
In conclusion, the results of this subgroup analysis of a real-world registry (EU-CORE) suggest that daptomycin was effective and well tolerated in the treatment of Gram-positive infections in patients with IE who underwent heart valve replacement. A trend towards better clinical outcomes was observed with high-dose daptomycin. The 2-year follow-up data indicated a high sustained response. Overall, the results suggest that daptomycin can be considered as an important treatment alternative in patients with IE who undergo heart valve replacement.
